

Nigel B Jamieson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6966097/publications.pdf>

Version: 2024-02-01

103
papers

12,404
citations

53794

45
h-index

38395

95
g-index

106
all docs

106
docs citations

106
times ranked

18332
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.	27.8	2,700
2	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	27.8	2,132
3	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	27.8	716
4	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2016, 29, 832-845.	16.8	645
5	Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 246-251.	7.1	530
6	Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late Endosomes/Lysosomes and Drive Cancer Progression. <i>Developmental Cell</i> , 2012, 22, 131-145.	7.0	275
7	Targeting the <scp>LOX</scp> / <scp>hypoxia</scp> axis reverses many of the features that make pancreatic cancer deadly: inhibition of <scp>LOX</scp> abrogates metastasis and enhances drug efficacy. <i>EMBO Molecular Medicine</i> , 2015, 7, 1063-1076.	6.9	223
8	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	6.3	223
9	MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 534-545.	7.0	192
10	Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. <i>Molecular Cell</i> , 2011, 42, 36-49.	9.7	179
11	Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2010, 251, 1003-1010.	4.2	178
12	Hypermutation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.	1.3	174
13	Paradoxical Elevation in Adiponectin Concentrations in Women With Preeclampsia. <i>Hypertension</i> , 2003, 42, 891-894.	2.7	148
14	Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. <i>Pancreatology</i> , 2006, 6, 450-453.	1.1	147
15	Drug induced pancreatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 143-155.	2.4	147
16	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2013, 31, 1348-1356.	1.6	142
17	Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy. <i>Annals of Surgery</i> , 2019, 269, 143-149.	4.2	142
18	Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. <i>British Journal of Cancer</i> , 2005, 92, 21-23.	6.4	136

#	ARTICLE	IF	CITATIONS
19	LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest. <i>Gastroenterology</i> , 2010, 139, 586-597.e6.	1.3	130
20	Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2010, 139, 292-303.	1.3	123
21	Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2018, 267, 608-616.	4.2	117
22	Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. <i>Clinical Cancer Research</i> , 2011, 17, 3316-3331.	7.0	114
23	Targeting mTOR dependency in pancreatic cancer. <i>Gut</i> , 2014, 63, 1481-1489.	12.1	107
24	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. <i>Cell Reports</i> , 2016, 14, 907-919.	6.4	107
25	Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 341-352.	3.8	105
26	A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 2318-2328.	1.5	104
27	IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. <i>Oncotarget</i> , 2014, 5, 11064-11080.	1.8	103
28	Ligand-Occupied Integrin Internalization Links Nutrient Signaling to Invasive Migration. <i>Cell Reports</i> , 2015, 10, 398-413.	6.4	101
29	Fascin Is Regulated by Slug, Promotes Progression of Pancreatic Cancer in Mice, and Is Associated With Patient Outcomes. <i>Gastroenterology</i> , 2014, 146, 1386-1396.e17.	1.3	100
30	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 1389-1404.	2.8	94
31	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. <i>Gastroenterology</i> , 2021, 160, 362-377.e13.	1.3	90
32	Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2017, 265, 978-986.	4.2	88
33	Defining the molecular pathology of pancreatic body and tail adenocarcinoma. <i>British Journal of Surgery</i> , 2018, 105, e183-e191.	0.3	88
34	Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 887-898.	1.7	80
35	The Prognostic Influence of Resection Margin Clearance Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 511-521.	1.7	80
36	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020, 31, 107625.	6.4	78

#	ARTICLE	IF	CITATIONS
37	Exploiting inflammation for therapeutic gain in pancreatic cancer. <i>British Journal of Cancer</i> , 2013, 108, 997-1003.	6.4	73
38	Gene-expression profiling to predict responsiveness to immunotherapy. <i>Cancer Gene Therapy</i> , 2017, 24, 134-140.	4.6	72
39	Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy. <i>Hpb</i> , 2014, 16, 610-619.	0.3	67
40	The integrin $\alpha 6 \beta 1$ drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. <i>Journal of Pathology</i> , 2019, 249, 332-342.	4.5	66
41	Cyst Fluid Biomarkers for Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Critical Review from the International Expert Meeting on Pancreatic Branch-Duct-Intraductal Papillary Mucinous Neoplasms. <i>Journal of the American College of Surgeons</i> , 2015, 220, 243-253.	0.5	64
42	The Relationship Between Tumor Inflammatory Cell Infiltrate and Outcome in Patients with Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3581-3590.	1.5	61
43	Serum amylase and C-reactive protein in risk stratification of pancreas-specific complications after pancreaticoduodenectomy. <i>British Journal of Surgery</i> , 2016, 103, 553-563.	0.3	60
44	Outcome after surgical resection for duodenal adenocarcinoma in the UK. <i>British Journal of Surgery</i> , 2015, 102, 676-681.	0.3	55
45	Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. <i>Clinical Endocrinology</i> , 2020, 92, 396-406.	2.4	51
46	SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0131344.	2.5	51
47	Precision Oncology in Surgery. <i>Annals of Surgery</i> , 2020, 272, 366-376.	4.2	48
48	Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. <i>Cytokine</i> , 2004, 27, 90-92.	3.2	46
49	Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2021, 274, 1051-1057.	4.2	43
50	The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2019, 270, 147-157.	4.2	43
51	Clinical Potential of MicroRNAs in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2011, 40, 1165-1171.	1.1	42
52	Identification of an Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically Relevant Fistula After Distal Pancreatectomy. <i>Annals of Surgery</i> , 2019, 269, 337-343.	4.2	42
53	Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. <i>British Journal of Surgery</i> , 2019, 106, 342-354.	0.3	38
54	Adiponectin Predicts Insulin Resistance But Not Endothelial Function in Young, Healthy Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4615-4621.	3.6	37

#	ARTICLE	IF	CITATIONS
55	Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 272, 1086-1093.	4.2	36
56	Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. <i>British Journal of Surgery</i> , 2020, 107, 1171-1182.	0.3	34
57	Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. <i>Chinese Clinical Oncology</i> , 2019, 8, 16-16.	1.2	33
58	Expression of KOC, S100P, mesothelin and MUC1 in pancreatobiliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. <i>BMC Clinical Pathology</i> , 2014, 14, 35.	1.8	32
59	AKT regulates NPM dependent ARF localization and p53mut stability in tumors. <i>Oncotarget</i> , 2014, 5, 6142-6167.	1.8	30
60	A microRNA meta-signature for pancreatic ductal adenocarcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 267-271.	3.1	29
61	Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. <i>BMC Genomics</i> , 2010, 11, 532.	2.8	27
62	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. <i>Communications Biology</i> , 2021, 4, 155.	4.4	26
63	Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 512-524.	1.7	25
64	PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. <i>Clinical Oncology</i> , 2020, 32, 1-4.	1.4	23
65	Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 218-224.	1.0	22
66	RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas. <i>Modern Pathology</i> , 2020, 33, 657-664.	5.5	22
67	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. <i>Surgery</i> , 2021, 169, 708-720.	1.9	22
68	Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 38-48.	7.3	20
69	Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 68-76.	1.7	19
70	Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1717-1726.	1.0	17
71	Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. <i>Clinical Oncology</i> , 2020, 32, 5-8.	1.4	15
72	Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. <i>Clinical Cancer Research</i> , 2022, 28, 4056-4069.	7.0	14

#	ARTICLE	IF	CITATIONS
73	Pancreatic cancer genomics: where can the science take us?. <i>Clinical Genetics</i> , 2015, 88, 213-219.	2.0	13
74	Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head. <i>Pancreas</i> , 2020, 49, 621-628.	1.1	13
75	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 683-695.	1.4	12
76	Observation or resection of pancreatic intraductal papillary mucinous neoplasm: An ongoing tug of war. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 1092-1100.	2.0	12
77	The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. <i>Surgery</i> , 2021, 170, 1195-1204.	1.9	11
78	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. <i>Nature Communications</i> , 2021, 12, 6738.	12.8	10
79	Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 224-229.	1.1	9
80	Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2248-2255.	1.0	8
81	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2543-2550.	1.0	8
82	Management of post-pancreatectomy haemorrhage using resuscitative endovascular balloon occlusion of the aorta. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 253-255.	1.9	7
83	Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. <i>Frontiers in Medicine</i> , 2020, 7, 385.	2.6	7
84	Cancer Genetics and Implications for Clinical Management. <i>Surgical Clinics of North America</i> , 2015, 95, 919-934.	1.5	6
85	Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer Agreement. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 599-608.	1.2	6
86	A national survey of attitudes to research in Scottish General Surgery Trainees. <i>Scottish Medical Journal</i> , 2014, 59, 9-15.	1.3	5
87	Can we move towards personalised pancreatic cancer therapy?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 335-338.	3.0	5
88	A Glasgow Tippleâ€™transjugular intrahepatic portosystemic shunt insertion prior to Whipple resection. <i>Journal of Surgical Case Reports</i> , 2016, 2016, rjw089.	0.4	4
89	ROR1 and ROR2 expression in pancreatic cancer. <i>BMC Cancer</i> , 2021, 21, 1199.	2.6	4
90	Comparison of simple acid-ethanol precipitation with gel exclusion chromatography for measuring leptin binding in serum of normal subjects and cancer patients. <i>Annals of Clinical Biochemistry</i> , 2003, 40, 185-187.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Investigation and management of pancreatic tumours. <i>Frontline Gastroenterology</i> , 2014, 5, 144-152.	1.8	2
92	Immuno-Oncology in Pancreatic Cancer. , 2021, , 287-304.		2
93	Routine Drainage After Pancreaticoduodenectomy. <i>Annals of Surgery</i> , 2015, 262, e107.	4.2	1
94	Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities. , 2015, , 375-395.		1
95	RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv204.	6.3	1
96	Influence of IP-10/CXCL10 induction in human pancreatic cancer stroma on lymphocytes recruitment and correlation with survival.. <i>Journal of Clinical Oncology</i> , 2015, 33, 290-290.	1.6	1
97	The Challenges of Improving Survival Following Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2011, 254, 386.	4.2	0
98	Reply to G.F. Arroyo. <i>Journal of Clinical Oncology</i> , 2013, 31, 3843-3844.	1.6	0
99	Stratified Medicine for Pancreatic Cancer. , 2014, , 807-814.		0
100	Molecular Subtyping of Pancreatic Cancer. , 2021, , 305-319.		0
101	Role of neoadjuvant treatment regimens for locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 444-444.	1.6	0
102	Feasibility and clinical utility of EUS guided biopsy of pancreatic cancer for next-generation genomic sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15755-e15755.	1.6	0
103	Markov decision analysis of neoadjuvant treatment pathway versus surgery first pathway for resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 456-456.	1.6	0